Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vaxcyte, Inc.
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
December 03, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
November 12, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
November 05, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
September 11, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 06, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
September 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
September 03, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 03, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Appoints John Furey to Board of Directors
July 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
March 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 15, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 02, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
February 01, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Announces Pricing of $750 Million Public Offering
January 30, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 30, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
January 29, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Appoints Whitney Jones as Chief People Officer
January 16, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
January 04, 2024
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
December 04, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Appoints Jacks Lee to Board of Directors
November 28, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
November 27, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
STRO
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
November 09, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
November 06, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte to Present at Upcoming Investor Conferences
October 31, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
October 16, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Tickers
PCVX
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.